Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
about
Cell Proliferation in NeuroblastomaSmall molecule induced reactivation of mutant p53 in cancer cellsA p53 drug response signature identifies prognostic genes in high-risk neuroblastomaAttenuation of soft-tissue sarcomas resistance to the cytotoxic action of TNF-α by restoring p53 functionCombined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models.High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma.MDM2 antagonist nutlin-3a reverses mitoxantrone resistance by inhibiting breast cancer resistance protein mediated drug transportMyc proteins as therapeutic targets.Identification of BIRC6 as a novel intervention target for neuroblastoma therapy.Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration.Galectin-3 impairment of MYCN-dependent apoptosis-sensitive phenotype is antagonized by nutlin-3 in neuroblastoma cellsInhibitory effect of tumor suppressor p53 on proinflammatory chemokine expression in ovarian cancer cells by reducing proteasomal degradation of IκB.Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP.WIP1 phosphatase as a potential therapeutic target in neuroblastomaProgesterone inhibits the growth of human neuroblastoma: in vitro and in vivo evidence.Neuroblastoma: molecular pathogenesis and therapy.Translational approaches targeting the p53 pathway for anti-cancer therapy.G-CSF Promotes Neuroblastoma Tumorigenicity and Metastasis via STAT3-Dependent Cancer Stem Cell Activation.Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomasMolecular mechanisms of MYCN-dependent apoptosis and the MDM2-p53 pathway: an Achille's heel to be exploited for the therapy of MYCN-amplified neuroblastoma.Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing ProgramRING finger protein 31 promotes p53 degradation in breast cancer cells.Targeting the p53 pathway.Downregulation of cyclin D1 sensitizes cancer cells to MDM2 antagonist Nutlin-3Wip1 inhibitor GSK2830371 inhibits neuroblastoma growth by inducing Chk2/p53-mediated apoptosis.Essential Roles of E3 Ubiquitin Ligases in p53 Regulation.Resistance acquisition to MDM2 inhibitors.Neuroblastoma models for insights into tumorigenesis and new therapies.Nutlin-3, A P53-Mdm2 Antagonist For Nasopharyngeal Carcinoma Treatment.Co-targeting of FAK and MDM2 triggers additive anti-proliferative effects in mesothelioma via a coordinated reactivation of p53.Treatment with a BH3 mimetic overcomes the resistance of latency III EBV (+) cells to p53-mediated apoptosis.Nutlin-3 sensitizes nasopharyngeal carcinoma cells to cisplatin-induced cytotoxicity.Pharmacological activation of wild-type p53 in the therapy of leukemia.Structurally diverse MDM2-p53 antagonists act as modulators of MDR-1 function in neuroblastoma.TRIAD1 Is a Novel Transcriptional Target of p53 and Regulates Nutlin-3a-Induced Cell Death.Effects of MDM2 inhibitors on vascular endothelial growth factor-mediated tumor angiogenesis in human breast cancer.Attractor landscape analysis reveals feedback loops in the p53 network that control the cellular response to DNA damage.Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells.TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation
P2860
Q26771708-DF5C139E-06D6-4F9F-A9BD-E68CCE2934E7Q27677872-D7C082FE-DDEF-4288-918B-62DF5A4010CBQ28537647-0425D3F7-D69C-4143-A7F3-A851AD4D8827Q28728301-B03FF631-30B1-496F-BA08-79B6F61016F7Q33699808-3BAF3BEB-FCED-4B30-8F0A-2926879B4B2DQ33743767-77A72D44-85AF-4882-9417-88840B940FA0Q33860877-BA83ED6A-77C4-4131-BA2C-900D8AF2C854Q33997741-50B60E72-C078-4DE4-8EA3-FEAEE22BEC2CQ34334471-145F5163-A925-4E9C-9E84-FEB936F7394AQ34458379-4662231C-C734-43BF-9DD8-6C35A4BC1F5AQ34477775-11E31E12-2FD5-42CB-92A5-99D8C25D7982Q34540087-8E87A016-2610-4B36-991F-0F1FB691E972Q35011473-071542F0-361F-489D-B731-F61E37FDEDCFQ35058327-13A8385F-001F-4463-88AE-CA4EC61AD854Q35286790-1002AF80-9E71-4972-B177-16D4A567407DQ35564199-8865BB05-1B8A-4D76-932F-F55B33288557Q35708113-3D51E2A4-7C72-4AF0-9413-545FFA216549Q35752008-371B1FCA-E25D-4071-80EC-6F9C766C2C02Q36048192-6FC34AFE-3206-490D-BB9C-FAC5A0AFC958Q36313712-696E350B-5DEE-4861-996B-8913AED73B06Q36392660-1CF0E8CC-B970-4BF9-BA68-76436D47A227Q36804413-B8E194A0-22C0-4BEC-AD53-EA35033B702DQ37260683-CAD9B37F-66B3-4B80-9996-B380120EF028Q37362736-9B1BC42C-EC82-4C34-82F1-26ADF22700DDQ37518896-D5F3DEB1-4C97-4BAD-A10B-BFE293007E34Q37691041-079EF393-11CF-412F-934A-FF7B8A8D5C66Q38238600-EFF13D02-4166-4931-A23C-209FA6AFEE0AQ38262762-A96B3FBF-FA42-494A-9150-5312CFFBBB92Q38656647-F60E86BC-1851-4B94-BD97-D5B678DE5EADQ38741344-4482DB54-3D27-4194-9E74-26F190280ADDQ38798819-AE06816F-D9CD-4BFF-A52C-A19DEC13F222Q38845519-B6F484F0-C1CE-40A7-8B5C-7E8CDA10F024Q38872029-22113A85-B4D6-4838-90FE-EA9C0CB6B441Q38985584-00130C6B-198A-4A5B-AFDB-DEBE87EFF3B9Q39116016-7D32A51A-C301-4646-B668-1EBDBD3D74ECQ39116877-227A57CA-B008-4218-AD01-C1C8D49420DCQ39241369-1CD71AB0-7CF3-45A4-9730-6F46AD103660Q39560187-E69B1419-A0A3-4D6C-8841-FFF7D9C5BA0EQ40209862-5D62209E-9CCA-4C04-9AD5-1DB9D7989C36Q40854245-164281B0-25FD-4B0D-BF74-0952437173B4
P2860
Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Antitumor activity of the sele ...... roblastoma with wild-type p53.
@ast
Antitumor activity of the sele ...... roblastoma with wild-type p53.
@en
type
label
Antitumor activity of the sele ...... roblastoma with wild-type p53.
@ast
Antitumor activity of the sele ...... roblastoma with wild-type p53.
@en
prefLabel
Antitumor activity of the sele ...... roblastoma with wild-type p53.
@ast
Antitumor activity of the sele ...... roblastoma with wild-type p53.
@en
P2093
P50
P356
P1476
Antitumor activity of the sele ...... roblastoma with wild-type p53.
@en
P2093
Claude A Cuvelier
Irina Lambertz
Jasmien Taildeman
Jindrich Cinatl
Liesbeth Ferdinande
Liesbeth Vercruysse
Marc Bracke
Tom Van Maerken
P304
P356
10.1093/JNCI/DJP355
P407
P50
P577
2009-11-10T00:00:00Z